A4250 for treating progressive familial intrahepatic cholestasis [ID1570]
In development [GID-HST10031] Expected publication date: TBC
Search results
489 results
-
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: TBC
-
Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]
In development [GID-HST10030] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-HST10023] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Metreleptin for treating lipodystrophy (ID861)
In development [GID-HST10011] Expected publication date: 13 January 2021
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]
In development [GID-HST10015] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID1477]
In development [GID-TA10448] Expected publication date: 07 October 2020
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
BCX7353 for preventing acute angioedema attacks in people 12 and over with hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: TBC
-
Recombinant human parathyroid hormone for treating hypoparathyroidism [1094]
Technology appraisal [TA625] Published date: 04 March 2020
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]
In development [GID-TA10610] Expected publication date: TBC
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: TBC
-
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Oleogel-S10 for treating epidermolysis bullosa [ID1505]
In development [GID-TA10654] Expected publication date: TBC
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
In development [GID-TA10655] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: TBC
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483) [ID1559]
In development [GID-TA10516] Expected publication date: TBC
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585
In development [GID-TA10538] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: 12 August 2020
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: TBC